CBD (Cannabidiol)
Non-psychoactive cannabinoid that promotes apoptosis/autophagy, suppresses NF-κB/angiogenesis; preclinical promise as chemo/radiation adjunct with CYP interaction caveats.
Forms: CBD oil/tincture (various concentrations) · CBD capsules (10–100 mg)
Simple Summary
Non-intoxicating CBD can push cancer cells toward apoptosis, dial down NF-κB inflammation, and reduce new blood-vessel growth in lab models. Early human oncology data are limited; watch for drug interactions (strong CYP2C19/3A4 inhibition) and liver-enzyme elevations at higher doses.
Evidence at a glance
Preclinical dominant with emerging adjunct signals; limited direct human oncology outcomes.
How it may work
CBD activates TRPV1 and PPAR-γ receptors, reducing tumor cell proliferation and inducing apoptosis via caspase activation. It downregulates Id-1, a metastasis-promoting gene, and inhibits angiogenesis by suppressing VEGF and MMPs. CBD also reduces NF-κB signaling, decreasing inflammation-driven tumor growth, and modulates CB1/CB2 receptors to disrupt cancer cell migration. Emerging evidence suggests CBD enhances chemotherapy and radiation therapy efficacy by promoting autophagic cell death and overcoming resistance.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
- TRPV1 / PPAR-γ↑Reduces proliferation; induces apoptosis
- Id-1↓Suppresses metastasis
- Angiogenesis↓VEGF / MMPs suppressed
- NF-κB↓Reduces inflammation-driven growth
- CB1/CB2 receptorsModulationDisrupts migration
- Apoptosis / Autophagy↑
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Temozolomide: Enhances apoptosis; reduces resistance.
- Cisplatin: Synergistic cytotoxicity; resistance reversal.
- Radiation: Potentiates tumor cell death.
- Curcumin: Complementary anti-inflammatory/apoptosis.
Overlapping mechanisms
- NF-κB ↓: Avoid stacking with other strong NF-κB inhibitors without monitoring for additive effects.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- CYP3A4/2C19 substrates (e.g., clobazam, warfarin, TKIs, chemo)MonitorMajorTheoreticalCBD inhibits CYP → ↑ exposure/toxicity.
- Sedatives/CNS depressantsMonitorModerateTheoreticalAdditive drowsiness.
- Chemotherapy (e.g., TMZ, cisplatin)ConsiderBeneficialTheoreticalPotential synergy for efficacy/resistance reversal; monitor levels/AEs.
Timing
- With fatty meal: Enhances bioavailability.
- Divided doses: AM/PM for steady levels; evening if somnolence an issue.
References
Research
No published studies for CBD (Cannabidiol) yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 200–800 mg (po) Divided into 2–3 doses daily. Oncology adjunct exploratory; ASCO advises against >300 mg/day outside trials, but studies use up to 800 mg/day for symptoms. Start low; titrate with monitoring., No Rx for non-Epidiolex forms. Full-spectrum may enhance effects (entourage); isolate for precision. Take with fatty meal for bioavailability. Clinician oversight essential for oncology..
Trials studying CBD (Cannabidiol)
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Appears in these protocol claims
CBD (Cannabidiol) is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
- Joe Tippens / Fenbendazole Protocol : Fenbendazole-centered supplement stack popularized through a remission story and online groups.
- Gerson, Gonzalez, Budwig, RSO, IPT, and Other Long-Running Claims : Older alternative or clinic-based approaches with strong testimonial communities and major evidence disputes.